Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with regional hyperthermia as second-line therapy for advanced pancreatic cancer
2005-003855-11Phase 2Recruiting
- Sponsor
- Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze. Primary endpoint: progression-free survival. Started Jun 2006; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2005-003855-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003855-11.